The global blood screening market was valued at USD 2.31 billion in 2018 and is anticipated to grow to USD 6.63 billion by 2032, reflecting a compound annual growth rate (CAGR) of 7.9% over the forecast period. In 2018, North America led the global market, accounting for 41.86% of the total share.
The blood screening market plays a vital role in ensuring the safety of blood transfusions and early detection of infectious diseases. It involves the testing of donated blood for a variety of transmissible pathogens such as HIV, hepatitis B and C, syphilis, and other infections that pose significant health risks. With rising global awareness around blood safety and the increasing demand for reliable diagnostic solutions, the market is witnessing steady growth. Advancements in screening technologies, including nucleic acid testing and immunoassays, have enhanced the accuracy and speed of detection, making blood screening more efficient and accessible. The market is also being driven by the growing number of blood donations, expanding healthcare infrastructure in emerging economies, and government initiatives promoting voluntary blood donation and safety standards. As the need for safe blood continues to grow across medical and surgical applications, the blood screening market is expected to remain a crucial component of global healthcare systems.
Tariff Impact Analysis for Blood Screening Market:
https://www.fortunebusinessinsights.com/blood-screening-market-102552
Blood Screening Market Overview:
The blood screening market is witnessing steady growth driven by an increasing need for safe blood transfusion, rising prevalence of infectious diseases, and advancements in screening technologies. The growing emphasis on healthcare safety protocols across both developed and developing nations further strengthens market expansion.
Market Trend:
A key trend driving the Blood Screening Market is the growing adoption of nucleic acid testing (NAT), which offers higher sensitivity and faster detection of bloodborne pathogens. Automation and integration of advanced technologies in screening platforms are also on the rise, helping laboratories improve accuracy and throughput. Moreover, the trend of decentralized testing in blood banks and community healthcare centers is gaining popularity, making screening more accessible and efficient.
Market Segmentation:
The blood screening market is broadly segmented based on technology, product type, and end-users. In terms of technology, the market includes nucleic acid testing (NAT), enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), and rapid testing methods. NAT is gaining significant traction due to its high sensitivity in detecting viral pathogens early in the infection cycle. ELISA remains widely used for routine screenings because of its reliability and cost-effectiveness, while CLIA offers enhanced automation and precision. On the basis of product type, the market is divided into reagents and kits, instruments, and software and services. Reagents and kits account for a large portion of the market, as they are essential for conducting accurate tests, while instruments and software play a supporting role in test execution and data analysis. Regarding end-users, the blood screening market serves blood banks, hospitals, and diagnostic laboratories. Blood banks represent a major share due to the constant demand for safe blood supplies, whereas hospitals and labs utilize screening technologies for pre-surgical assessments and routine diagnostics. This comprehensive segmentation highlights the diverse applications and users that drive the demand for blood screening solutions across the healthcare ecosystem.
List Of Key Companies Profiled: